课题基金 / 基金详情

Prognostic Biomarkers and Novel Therapies for Oral Squamous Cell Carcinoma Patients

Prognostic Biomarkers and Novel Therapies for Oral Squamous Cell Carcinoma Patients
口腔鳞状细胞癌患者的预后生物标志物和新疗法
批准号:
408426
负责人:
Ailles Laurie E
金额:
$76.63万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2019
资助国家:
加拿大
项目状态:
已结题
起止时间:
2019-09-01 至 2024-09-01

项目摘要

项目成果

Ailles Laurie E的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Patients with head and neck cancer have a 50% 5-year survival. Patients are treated with surgery, and may also receive radiation therapy, or combined radiation and chemotherapy. These therapies are very toxic and can have long-term negative side effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting PRMT1 in Clear Cell Renal Cell Carcinoma
Targeting PRMT1 in Clear Cell Renal Cell Carcinoma
Functional and Genetic Heterogeneity in Oral Squamous Cell Carcinoma
Functional and Molecular Characterization of Cancer-Associated Fibroblasts in High Grade Serous Ovarian Cancer
海外基金